Cargando…

Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor In Vitro and In Vivo

Curcumin (Cur) exhibits biological activities that support its candidacy for cancer treatment. However, there are limitations to its pharmacological effects, such as poor solubility and bioavailability. Notably, the use of Cur analogs has potential for addressing these limitations. Dehydrozingerone...

Descripción completa

Detalles Bibliográficos
Autores principales: Mapoung, Sariya, Suzuki, Shugo, Fuji, Satoshi, Naiki-Ito, Aya, Kato, Hiroyuki, Yodkeeree, Supachai, Sakorn, Natee, Ovatlarnporn, Chitchamai, Takahashi, Satoru, Limtrakul (Dejkriengkraikul), Pornngarm
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356390/
https://www.ncbi.nlm.nih.gov/pubmed/32545675
http://dx.doi.org/10.3390/molecules25122737
_version_ 1783558488242257920
author Mapoung, Sariya
Suzuki, Shugo
Fuji, Satoshi
Naiki-Ito, Aya
Kato, Hiroyuki
Yodkeeree, Supachai
Sakorn, Natee
Ovatlarnporn, Chitchamai
Takahashi, Satoru
Limtrakul (Dejkriengkraikul), Pornngarm
author_facet Mapoung, Sariya
Suzuki, Shugo
Fuji, Satoshi
Naiki-Ito, Aya
Kato, Hiroyuki
Yodkeeree, Supachai
Sakorn, Natee
Ovatlarnporn, Chitchamai
Takahashi, Satoru
Limtrakul (Dejkriengkraikul), Pornngarm
author_sort Mapoung, Sariya
collection PubMed
description Curcumin (Cur) exhibits biological activities that support its candidacy for cancer treatment. However, there are limitations to its pharmacological effects, such as poor solubility and bioavailability. Notably, the use of Cur analogs has potential for addressing these limitations. Dehydrozingerone (DZG) is a representative of the half-chemical structure of Cur, and many reports have indicated that it is anticancer in vitro. We, therefore, have hypothesized that DZG could inhibit prostate cancer progression both in vitro and in vivo. Results revealed that DZG decreased cell proliferation of rat castration-resistant prostate cancer, PLS10 cells, via induction of the cell cycle arrest in the G1 phase in vitro. In the PLS10 xenograft model, DZG significantly decreased the growth of subcutaneous tumors when compared to the control via the inhibition of cell proliferation and angiogenesis. To prove that DZG could improve the limitations of Cur, an in vivo pharmacokinetic was determined. DZG was detected in the serum at higher concentrations and remained up to 3 h after intraperitoneal injections, which was longer than Cur. DZG also showed superior in vivo tissue distribution than Cur. The results suggest that DZG could be a candidate of the Cur analog that can potentially exert anticancer capabilities in vivo and thereby improve its bioavailability.
format Online
Article
Text
id pubmed-7356390
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73563902020-07-30 Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor In Vitro and In Vivo Mapoung, Sariya Suzuki, Shugo Fuji, Satoshi Naiki-Ito, Aya Kato, Hiroyuki Yodkeeree, Supachai Sakorn, Natee Ovatlarnporn, Chitchamai Takahashi, Satoru Limtrakul (Dejkriengkraikul), Pornngarm Molecules Article Curcumin (Cur) exhibits biological activities that support its candidacy for cancer treatment. However, there are limitations to its pharmacological effects, such as poor solubility and bioavailability. Notably, the use of Cur analogs has potential for addressing these limitations. Dehydrozingerone (DZG) is a representative of the half-chemical structure of Cur, and many reports have indicated that it is anticancer in vitro. We, therefore, have hypothesized that DZG could inhibit prostate cancer progression both in vitro and in vivo. Results revealed that DZG decreased cell proliferation of rat castration-resistant prostate cancer, PLS10 cells, via induction of the cell cycle arrest in the G1 phase in vitro. In the PLS10 xenograft model, DZG significantly decreased the growth of subcutaneous tumors when compared to the control via the inhibition of cell proliferation and angiogenesis. To prove that DZG could improve the limitations of Cur, an in vivo pharmacokinetic was determined. DZG was detected in the serum at higher concentrations and remained up to 3 h after intraperitoneal injections, which was longer than Cur. DZG also showed superior in vivo tissue distribution than Cur. The results suggest that DZG could be a candidate of the Cur analog that can potentially exert anticancer capabilities in vivo and thereby improve its bioavailability. MDPI 2020-06-12 /pmc/articles/PMC7356390/ /pubmed/32545675 http://dx.doi.org/10.3390/molecules25122737 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mapoung, Sariya
Suzuki, Shugo
Fuji, Satoshi
Naiki-Ito, Aya
Kato, Hiroyuki
Yodkeeree, Supachai
Sakorn, Natee
Ovatlarnporn, Chitchamai
Takahashi, Satoru
Limtrakul (Dejkriengkraikul), Pornngarm
Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor In Vitro and In Vivo
title Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor In Vitro and In Vivo
title_full Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor In Vitro and In Vivo
title_fullStr Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor In Vitro and In Vivo
title_full_unstemmed Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor In Vitro and In Vivo
title_short Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor In Vitro and In Vivo
title_sort dehydrozingerone, a curcumin analog, as a potential anti-prostate cancer inhibitor in vitro and in vivo
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356390/
https://www.ncbi.nlm.nih.gov/pubmed/32545675
http://dx.doi.org/10.3390/molecules25122737
work_keys_str_mv AT mapoungsariya dehydrozingeroneacurcuminanalogasapotentialantiprostatecancerinhibitorinvitroandinvivo
AT suzukishugo dehydrozingeroneacurcuminanalogasapotentialantiprostatecancerinhibitorinvitroandinvivo
AT fujisatoshi dehydrozingeroneacurcuminanalogasapotentialantiprostatecancerinhibitorinvitroandinvivo
AT naikiitoaya dehydrozingeroneacurcuminanalogasapotentialantiprostatecancerinhibitorinvitroandinvivo
AT katohiroyuki dehydrozingeroneacurcuminanalogasapotentialantiprostatecancerinhibitorinvitroandinvivo
AT yodkeereesupachai dehydrozingeroneacurcuminanalogasapotentialantiprostatecancerinhibitorinvitroandinvivo
AT sakornnatee dehydrozingeroneacurcuminanalogasapotentialantiprostatecancerinhibitorinvitroandinvivo
AT ovatlarnpornchitchamai dehydrozingeroneacurcuminanalogasapotentialantiprostatecancerinhibitorinvitroandinvivo
AT takahashisatoru dehydrozingeroneacurcuminanalogasapotentialantiprostatecancerinhibitorinvitroandinvivo
AT limtrakuldejkriengkraikulpornngarm dehydrozingeroneacurcuminanalogasapotentialantiprostatecancerinhibitorinvitroandinvivo